Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
Key Highlights
- ➤Celularity regained Nasdaq periodic reporting compliance after filing its June 30, 2026 10-Q
- ➤Nasdaq closed all three deficiency matters, including bid price and market value requirements
- ➤Celularity began overhauling its finance organization after repeated late financial filings
- ➤Robert J. Hariri took responsibility for Celularity’s recurring delayed financial reporting
Expert Statements
Robert J. Hariri, Chairman and Chief Executive Officer of Celularity
“We have repeatedly fallen short of our obligation to provide timely financial reporting, and I take responsibility for that”
Robert J. Hariri, Chairman and Chief Executive Officer of Celularity
“Our shareholders deserve better. With our filings now current, we must address the recurring delays. We have begun a process to overhaul our finance organization and establish the reporting discipline expected of a public company.”
Philip A. Barach, Recently appointed director and investor in Celularity
“The need to strengthen the finance organization was clear when I invested in Celularity, and the late filings did not change my conviction in Celularity’s science and commercial potential.”
Philip A. Barach, Recently appointed director and investor in Celularity
“The Board is working with Dr. Hariri to identify experienced finance professionals who can carry that work forward. Our focus is on building a team that can consistently meet ongoing financial reporting obligations as we aggressively pursue the opportunities ahead.”
FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.
Nasdaq’s determination follows Celularity’s October 20, 2026 filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2026. Nasdaq confirmed that the reporting deficiency matter is now closed.
Get started
Create a free account to read the full story.